Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 117-124

  Velez, Michel ^a   Arango, Belisario A ^a   Perez, Cesar A ^a   Santos, Edgardo S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Lung cancer; Maintenance; Pemetrexed

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PEMETREXED; PLACEBO;

ANEMIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DIVERTICULITIS; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; SURVIVAL TIME; THROMBOCYTOPENIA; VEIN THROMBOSIS; VOMITING;

EID: 84857830969     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6248     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
2. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV Non-Small Cell Lung Cancer. J Clin Oncol. 2002;1335-43.
3. Barata FJ, Parente B, Teixeira E, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs. 6 cycles of carboplatin and gemcitabine: P2-235. J Thorac Oncol. 2007;2(Suppl 4):S666.
4. Park JO, Kim S-W, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007:5233-9.
5. Soon Y, Stockler MR, Boyer M, Askie L. Duration of chemotherapy for advanced non-small-cell lung cancer: An updated systematic review and meta-analysis. J Clin Oncol. 2008;26(15S):8013.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002: 92-8.
7. Ciuleanu T, Brodowicz T, Zielinski, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non small cell lung cancer: a randomized, double blind, phase 3 study. Lancet. 2009:1432-40.
8. Capuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance t{stroke}reatment in advanced non-small-cell lung cancer: a multicenter, randomized, placebo-controlled phase 3 study. Lancet. 2010:521-9.
9. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006: 2542-50.
10. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell-lung cancer (FLEX): an open label randomized phase III trial. Lancet. 2009:1525-31.
11. Paz-Ares LG, De Marinis F, Dediu M, et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non small cell lung cancer(NSCLC). J Clin Oncol. 2011:29 (suppl abst CRA7510).
12. Brodowicz T, Krzaowski M, Zwitter M, et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine fist-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006:155-63.
13. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009:591-8.
14. Shepherd FA, Dancey J, Ramlau R, et al. Prospective Randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000:2095-103.
15. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006:1589-96. The DISTAL 01 study. Br J Cancer. 2004:1996-2004.
16. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997:1116-23.
17. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007:404-17.
18. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004:1589-97.
19. Cullen MH, Zatloukal P, Sorenson S, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2008:939-45.
20. Scagliotti G, Hanna N, Fosella F, et al. The differential efficacy of pemetrexed accosrding to NSCLC histology: A review of two phase III studies. The Oncologist. 2009:253-63.
21. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naive patients with advanced stage non-small-cell lung cancer. J Clin Oncol. 2008:3543-51.
22. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328. J Thorac Oncol. 2007;2(Suppl 4):s851.
23. Herbst RS, O'Neill VJ, Fehrenbacher, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol. 2007:4743-50.
24. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009:3284-9.
25. Barlesi F, Scherpereel A, Gervais R, et al. AVAPERL1 (MO22089): Maintenance (mtc) Bevacizumab (bev) with or without pemetrexed (pem) in patients with advanced nonsquamous non-small cell lung cancer treated with first-line bev-cisplatin-pem: Interim safety data. J Clin Oncol. 2011:29 (suppl abst 7562).
26. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the point break study: a randomized open label phase III study of pemetrexed/carboplatin/bavacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2009:252-6.
27. Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004:S51-55.
28. Adjei AA. Pemetrexed (Alimta), A novel multitargeted antineoplastic agent. Clin Cancer Res. 2004:4276S.
29. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther. 2005:1343-82.
30. Barlesi F, de Castro J, Dvornichenko V, et al. AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) with Advanced Non-Squamous Non-Small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pem) after First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). Eur J Cancer. 2011;47(Suppl 2):16(34LBA).